BAYREUTH;Germany, December 16, 2010 /PRNewswire/ -- BioCer Entwicklungs GmbH, a Bayreuth, Germany-based medical device manufacturer, are pleased to announce the CE approval of HaemoCer(TM), an Absorbable Polysaccharide Hemostat (APH). Introduction of HaemoCer(TM) APH will commence this month in the European Union and other selected international markets.
HaemoCer(TM) is an absorbable, surgical hemostatic technology created via a Polysacharide Ultra-hydrophilic Resorbable Engineering (PURE) process. PURE processing utilizes sophisticated, plant-based polymer crosslinking that creates ultra-hydrophilic, biocompatible, polysaccharide compounds. The PURE technology format of HaemoCer(TM) is a powder; alternate novel product formats are planned for release Q2 2011. A family of customized, single-use application instruments will enhance the delivery of HaemoCer(TM) particles to the wound site for the control of capillary, venous and arteriolar bleeding in both open and minimally invasive surgical procedures. There is no thrombin, collagen, or other human or animal components in HaemoCer(TM) particles.
Heinz-Josef Schmies, Managing Director of BioCer Entwicklungs Gmbh commented, "In conjunction with clinical trial results due Q1 2011, the introduction of HaemoCer(TM) APH and its proprietary, integrated PURE technology represents the next generation of polysaccharide hemostatic agents. Complete production of HaemoCer(TM) is conducted in Germany and has been warmly received by multi-disciplinary surgical specialists. Our technology has been favorably received in multiple international markets and fields."
BioCer Entwicklungs GmbH is a privately held medical device company and develops novel materials and uses them to create new or modified medical devices and manufacturing technologies. BioCer Entwicklungs current solutions incorporate ceramic, polysaccharide, polymer and other composite materials developed with leading Bavarian scientific expertise in collaboration the University of Bayreuth. The proprietary, patent-pending technology platform for HaemoCer(TM) and PURE processing will focus on the worldwide, hemostasis, wound care, hernia repair and orthopedic marketplaces. For information, distribution inquiries, and licensing options, visit http://www.biocer-gmbh.de/en/ Contact:info@biocer-gmbh.de
